- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04908046
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
Study Title A Multicenter, Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-295S1 in Treatment of the Patients With Advanced Malignant Solid Tumors
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Ronghua Zhang
- Phone Number: +86 15267110561
- Email: ronghuaz@hutch-med.com
Study Contact Backup
- Name: Yan Wu
- Phone Number: +86(0)21 20671770
- Email: yanw@hutch-med.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Qian Yu Dong
- Phone Number: 180 1731 7810
- Email: yuqian_dong@126.com
-
Principal Investigator:
- Xianjun Yu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All the following conditions must be met for enrollment:
- Having understood this study adequately and being voluntary to sign the informed consent form;
- Aged 18~75 years (inclusive);
- Patients with histopathologically or cytologically confirmed advanced malignant solid tumors who have failure of standard of care or can not tolerate standard of care, or can not obtain standard of care for various reasons, or have no standard of care (regardless of previous surgery);
- Having at least one measurable lesion (in accordance with the RECIST 1.1 criteria); note: the lesion previously irradiated can not be regarded as target lesion, unless unequivocal progression of disease is shown in radiological evidence after radiotherapy;
- United States Eastern Cooperative Oncology Group (ECOG) Performance Status score ≤ 1;
- Life expectancy ≥12 weeks based on investigator's judgment;
Having adequate bone marrow, hepatic and renal function (no transfusion of whole blood, blood components, blood products, no use of granulocyte colony-stimulating factor or other hematopoietic stimulator or drug for correction within two weeks prior to blood collection):
- Absolute neutrophil count ≥1.5×109/L;
- HGB≥90 g/L;
- Platelet count ≥ 100×109/L;
- Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) [alanine aminotransferase (ALT) and aspartate aminotransferase (AST) need to be normal, serum total bilirubin needs to be ≤3 × ULN in the patients with Gilbert disease];
- Serum ALT and/or AST ≤2.5 × ULN in the patients without hepatic metastasis (ALT and AST ≤5 ×ULN for those with liver metastasis);
- Creatinine clearance ≥ 60 mL/min (calculated according to Cockcroft-Gault formula, see Appendix 11);
- International normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (aPTT) ≤ 1.5 ULN.
- A man of childbearing potential and his heterosexual partner of childbearing age must agree to use effective contraceptive methods from the signature of informed consent form to 90 days after the last dose; any female of childbearing potential (including those who have received tubal ligation) must receive serum or urine pregnancy test and the result is negative within 7 days prior to the first dose of study drug; and she must agree to use effective contraceptive methods, for example, dual barrier contraceptive method, intrauterine device, etc., from the signature of informed consent form to 30 days after the last dose of study drug. Postmenopausal woman (age > 50 years and menopause for 1 year or above, in the absence of other biological or physiological reasons) and the woman receiving irreversible sterilization operation (including hysterectomy, bilateral ovariectomy or bilateral salpingectomy, but excluding tubal ligation) who is regarded as infertile, will not be restricted by this condition.
Exclusion Criteria:
The patients can not participate in this study if any of the following conditions is met:
Previous antitumor therapy meeting any of the following:
- Previous treatment with a ERK inhibitor and having PD;
- Receiving approved systematic antitumor therapy within 4 weeks prior to the first dose, including chemotherapy, targeted therapy, immunotherapy, biotherapy, etc. (elution for two weeks for hormone therapy or treatment with traditional Chinese medicine and Chinese patent drug with clear antitumor indication);
- In the treatment period of other interventional clinical study (including small molecular chemical drug and macromolecular antibody) within 4 weeks prior to the first dose. Patients can be enrolled in this study if they are involved in non-interventional clinical study (e.g., epidemiological study); and can also be enrolled if they stay in the survival follow-up period of one interventional clinical study.
- Having received major surgery or radical radiotherapy (except for the palliative radiotherapy for bone metastasis) within 4 weeks prior to the first dose.
- Toxicity associated with previous antitumor therapy (including surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy) not recovered to ≤ CTCAE grade 1, except for alopecia and peripheral neuropathy. The peripheral neurotoxicity needs to be recovered to ≤ CTCAE grade 2 in the patients who have been previously treated with platinum;
- Patients with central nervous system (CNS) malignant tumor or malignant solid tumor with known CNS metastasis;
- Combined with other malignant tumor or having a history of other malignant tumor within 2 years prior to study screening (not including the basal or squamous cell carcinoma of skin, non-melanoma skin cancer, papillary thyroid carcinoma that have been appropriately treated, or radically resected cervical carcinoma in situ and ductal carcinoma in situ);
Known history of clinically significant liver disease, including viral or other hepatitis, except the following patients:
- HBsAg positive patients can be enrolled if the polymerase chain reaction (PCR) test of hepatitis B virus (HBV) DNA is negative. The investigator can provide preventive or therapeutic antiviral therapy based on patient's condition and diagnostic routines during study treatment;
- Patients with positive hepatitis C virus (HCV) antibody can be enrolled if the PCR test of HCV RNA is negative.
- Patients infected by human immunodeficiency virus (HIV);
- Presence of active bacterial, fungal or viral infection requiring systematic treatment within one week prior to the first dose;
- Use of CYP3A potent inducer within 2 week or 5 half-lives (whichever is longer, 3 weeks needed for St. John's wort) prior to the first dose, see (Appendix 5);
- Use of CYP3A, P-gp potent inhibitor or sensitive substrate of P-gp, BCRP, MATE 2-K, CYP3A, CYP2C8/OATP1B1 and CYP2D6/CYP3A within one week or three half-lives (whichever is longer) prior to the first dose, this exclusion criterion will be adjusted in accordance with the actual dose of HMPL-295S1 and determined plasma concentration during the clinical study (see Appendix 5);
Meeting any of the following criteria for cardiac examination:
- Hereditary long QT syndrome or QTcF>480 msec (the formula is seen in Appendix 10), or currently taking the drugs that are known to prolong QT interval or lead to torsade de pointe arrhythmia (Appendix 6);
- Serious arrhythmia or conduction abnormality requiring clinical intervention;
- Impaired cardiac function or clinically significant cardiac disease, including but not limited to the acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, New York Heart Association (NYHA, see Appendix 9) evaluated Grade III/IV congestive heart failure, left ventricular ejection fraction (LVEF) <50%, or uncontrollable hypertension within 6 months prior to enrollment.
- Pregnant or lactating women;
- Having multiple factors affecting absorption, distribution, metabolism or excretion of oral drugs, e.g., inability to swallow, frequent vomiting, chronic diarrhea, etc.;
- Currently known or previous retinopathy;
- Any other disease, metabolic abnormality, physical examination abnormality or clinically significant laboratory examination abnormality, one disease or state that may affect patient's compliance or provides a reason to suspect that the patient is not suitable to use the study drug, or will affect interpretation of the study results, or bring the patient at a high risk, according to investigator's judgment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HMPL-295S1 open-label treatment arm
During dose escalation, single-dose PK evaluation will be carried out firstly in each dose group. At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile. Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly. |
Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group. At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile. Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of oral HMPL-295S1 monotherapy for patients with advanced solid tumors;
Time Frame: from Cycle 0Day1 up to Cycle1Day28 (each cycle is 28 days)
|
Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observation Period.
|
from Cycle 0Day1 up to Cycle1Day28 (each cycle is 28 days)
|
Maximum tolerated dose (MTD)of oral HMPL-295S1.
Time Frame: MTD from 1st patient's Cycle 0Day1 (each cycle is 28 days) up to last patient's Last dose in escalation stage. (up to a maximum of approximately 2 years )
|
|
MTD from 1st patient's Cycle 0Day1 (each cycle is 28 days) up to last patient's Last dose in escalation stage. (up to a maximum of approximately 2 years )
|
Recommended phase II clinical study dose (RP2D) of oral HMPL-295S1.
Time Frame: Baseline up to last patient's last tumor assessment completed in escalation stage. (up to a maximum of approximately 2 years )
|
The investigator and the sponsor will determine RP2D jointly based on the following factors:
|
Baseline up to last patient's last tumor assessment completed in escalation stage. (up to a maximum of approximately 2 years )
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To investigate the pharmacokinetic (PK) profile of oral HMPL-295S1.
Time Frame: from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days)
|
Plasma peak concentration of HMPL-295S1 (Cmax)
|
from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days)
|
AUCinf (Cycle 0 ) of HMPL-295S1.
Time Frame: from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days)
|
AUCinf: area under the concentration vs. time curve from zero to infinity after single (first)dose.
|
from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days)
|
AUC(0-tlast) (Cycle 0 ) of HMPL-295S1.
Time Frame: from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days)
|
AUC from time zero to the last data point.
|
from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days)
|
Objective Response Rate (ORR)
Time Frame: From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
Percentage of patients with Complete Response(CR) or Partial Response(PR) as the best response evaluated in accordance with RECIST 1.1;
|
From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
Time to response (TTR)
Time Frame: From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
the time from the first dose of HMPL-295S1 to the first objective response.
|
From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
Duration of response (DoR)
Time Frame: From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
as the time from the first appearance of CR or PR to PD or death for any reason (whichever comes first), in the patients with objective response;
|
From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
Disease control rate (DCR)
Time Frame: From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
the proportion of patients with CR or PR or stable disease (SD) as the best response, and the duration of SD needs to be ≥6 weeks;
|
From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
Progression-free survival (PFS)
Time Frame: From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
time from the first dose of study treatment to PD or death for any reason, whichever comes first;
|
From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
Overall survival (OS)
Time Frame: From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
time from the first dose of study treatment to death for any reason.
|
From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory objective: To investigate the pharmacodynamic biomarkers of HMPL-295S1.
Time Frame: pre-dose to 4 hour after dose in Cycle1Day22(each cycle is 28 days)
|
Biomarkers in the blood specimen before and after treatment, phosphorylation level of ERK downstream signal ribosome S6 kinase (RSK).
|
pre-dose to 4 hour after dose in Cycle1Day22(each cycle is 28 days)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-295-00CH1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignant Solid Tumors
-
AnewPharmaCompleted
-
AnewPharmaCompletedAdvanced Malignant Solid TumorsChina
-
Stemirna TherapeuticsPeking University Cancer Hospital & InstituteNot yet recruitingAdvanced Malignant Solid Tumors
-
HutchmedRecruitingAdvanced Malignant Solid TumorsChina
-
AnewPharmaShanghai East HospitalActive, not recruitingAdvanced Malignant Solid TumorsChina
-
Millennium Pharmaceuticals, Inc.TerminatedAdvanced Malignant Solid TumorsUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerWithdrawnAdvanced Malignant Solid Tumors
-
Fudan UniversityUnknownAdvanced Malignant Solid TumorsChina
-
FindCure Biosciences (ZhongShan) Co., Ltd.RecruitingAdvanced Malignant Solid TumorsChina
Clinical Trials on HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted
-
Memorial Sloan Kettering Cancer CenterPfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of VirginiaCompletedNeurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial HemangiopericytomaUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedNon-Hodgkin's Lymphoma | CNS Lymphoma | CNS Brain CancerUnited States